Cleared Traditional

K212015 - BD Nano 2nd Gen Pen Needle

K212015 is an FDA 510(k) clearance for BD Nano 2nd Gen Pen Needle, manufactured by Becton, Dickinson and Company. The device is a Class 2 General Hospital device with product code FMI cleared through the Traditional 510(k) pathway after a 144-day FDA review.

K212015 · Becton, Dickinson and Company · General Hospital
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 2021
Decision
144d
Days
Class 2
Risk

K212015 is an FDA 510(k) clearance for the BD Nano 2nd Gen Pen Needle. Classified as Needle, Hypodermic, Single Lumen (product code FMI), Class II - Special Controls.

Submitted by Becton, Dickinson and Company (Franklin Lakes, US). The FDA issued a Cleared decision on November 19, 2021 after a review of 144 days - within the typical 510(k) review window.

This device falls under the General Hospital FDA review panel, regulated under 21 CFR 880.5570 - the FDA general hospital device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the General Hospital review framework, consistent with the majority of Class II 510(k) submissions.

View all Becton, Dickinson and Company devices

FDA 510(k) Submission Details - K212015

510(k) Number K212015 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 28, 2021
Decision Date November 19, 2021
Days to Decision 144 days
Submission Type Traditional
Review Panel General Hospital (HO)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
15d slower than avg
Panel avg: 129d · This submission: 144d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

FMI Device Classification - Class 2, Special Controls

Product Code FMI Needle, Hypodermic, Single Lumen
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 880.5570
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most General Hospital devices follow this clearance model.

Regulatory Peers - FMI Needle, Hypodermic, Single Lumen

All 271
Devices cleared under the same product code (FMI) and FDA review panel - the closest regulatory comparables to K212015.
UltiCare Disposable Pen Needles
K213407 · Ultimed Incorporated · Dec 2021
Blood Collection Needles
K200932 · Vacutest Kima Srl · Dec 2021
BD Nano 2nd Gen Pen Needle
K213156 · Becton, Dickinson and Company · Dec 2021
Insulin Pen Needle (Ordinary Type), Insulin Pen Needle (Safety Type)
K202319 · Tianjin Huahong Technology Co., Ltd. · Nov 2021
Sterile Hypodermic Needles for Single Use
K211214 · Azur Medical Company, Inc. · Oct 2021
SteriCap Mini Needle and Standard Needles
K212805 · Ocuject, LLC · Sep 2021